EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Cyclacel Pharmaceuticals's enterprise value is $-0.55 Mil.
Cyclacel Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.42 Mil. Therefore, Cyclacel Pharmaceuticals's EV-to-Revenue for today is -1.30.
The historical rank and industry rank for Cyclacel Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
CYCC'
s EV-to-Revenue Range Over the Past 10 Years
Min: -75.79 Med: -17.51 Max: 103.42
Current: -1.71
During the past 13 years, the highest EV-to-Revenue of Cyclacel Pharmaceuticals was 103.42. The lowest was -75.79. And the median was -17.51.
CYCC's EV-to-Revenue is ranked better than 95.44% of 1031
companies
in the Biotechnology industry
Industry Median: 7.91
vs CYCC: -1.71
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cyclacel Pharmaceuticals's EV-to-Revenue
For the Biotechnology subindustry, Cyclacel Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyclacel Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cyclacel Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Cyclacel Pharmaceuticals's EV-to-Revenue falls into.
Cyclacel Pharmaceuticals's current Enterprise Value is $-0.55 Mil.
Cyclacel Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclacel Pharmaceuticals's share price for today is $2.6802.
Cyclacel Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.50.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclacel Pharmaceuticals EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Cyclacel Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) Business Description
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CYCC has been successfully added to your 